Minnesota House Bill HF1652

Minnesota 2025-2026 Regular Session

• Introduced: 2/27/25
• Refer: 2/27/25

Caption

Health; formulary changes prohibited during the plan year.

Impact

This bill significantly impacts existing healthcare regulations, especially relating to the operations of health plans and their formularies. Under the proposed law, health plans may only alter their formularies under specific circumstances, including when a drug is deemed unsafe by the FDA or alternative, cheaper medications are made available. This regulatory change aims to protect enrollees from being subjected to unexpected drug removals or financial burdens within a plan year, theoretically helping maintain their continuity of care and medication adherence.

Summary

House Bill HF1652 seeks to mandate that health plans cannot remove drugs from their formularies nor increase costs for enrollees for medications that have been prescribed during the plan year. This legislation aims to provide stability and predictability for patients, ensuring they can continue their prescribed treatments without the fear of sudden changes to drug availability or cost structures. By making this provision effective from January 1, 2026, it emphasizes a clear transition period for health plans to adjust their operations accordingly.

Conclusion

In summary, HF1652 aims to provide stronger protections for enrollees against formulary changes during a plan year, which can have significant implications for healthcare access and affordability. Its passage could represent a shift towards more consumer-centric policies in health insurance, reflecting an increased legislative focus on patient experiences within the healthcare system.

Contention

Notably, there may be points of contention surrounding HF1652, focusing on the balance between protecting patients and maintaining the flexibility of health plans to manage their formularies. Opponents might argue that such restrictions could stifle the ability of health plans to adapt to new medical evidence and potentially limit their ability to negotiate better pricing with drug manufacturers. Conversely, proponents emphasize the necessity of patient protection and the importance of stable access to medications, especially for those with chronic conditions reliant on specific treatments.